Neuronetics Announces Appointment of Megan Rosengarten to its Board of Directors
August 05 2021 - 4:30PM
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical
technology company focused on designing, developing, and marketing
products that improve the quality of life for patients who suffer
from psychiatric disorders, today announced the appointment of
Megan Rosengarten as a new member of its Board of Directors.
Following her appointment, the Neuronetics’ Board of Directors now
has eight members.“I am very pleased to have Megan join
Neuronetics’ Board of Directors,” said Keith Sullivan, President
and Chief Executive Officer of Neuronetics, Inc. “Her background in
medical technology product development, marketing, and strategic
communications sets her apart as a highly qualified individual who
will help guide Neuronetics as we continue to seek to grow our
leadership position and bring the benefits of NeuroStar Advanced
Therapy for Mental Health to the people who need it.”Megan has
extensive experience in the healthcare sector, spanning over two
decades of marketing and strategic leadership. Megan serves as
President of Surgical Robotics at Medtronic, which is part of
Medtronic’s Medical Surgical portfolio. Prior to joining Medtronic,
she served as Vice President of Global Marketing at Hologic in the
Breast and Skeletal Health division. In addition, Megan held a
variety of roles in product management, marketing, and strategy at
Covidien and Johnson & Johnson. Megan earned a B.S. in
Biological Anthropology and Anatomy from Duke University, and an
M.B.A. from the University of North Carolina – Chapel Hill’s
Kenan-Flagler School of Business. “I'm honored to join Neuronetics
as a member of the Board of Directors,” said Megan Rosengarten.
“NeuroStar is a unique, highly effective therapy for a disease
state that impacts millions of patients annually. I am looking
forward to helping drive awareness among both customers and
patients, and ultimately drive the expanded adoption of NeuroStar
Advanced Therapy for Mental
Health.”
About NeuroneticsNeuronetics, Inc. is
a commercial-stage medical technology company focused on designing,
developing, and marketing products that improve the quality of life
for patients who suffer from psychiatric disorders. Our first
commercial product, the NeuroStar® Advanced Therapy System, is a
non-invasive and non-systemic office-based treatment that uses
transcranial magnetic stimulation, or TMS, to create a pulsed,
MRI-strength magnetic field that induces electrical currents
designed to stimulate specific areas of the brain associated with
mood. The system is cleared by the United States Food and Drug
Administration, or FDA, for the treatment of major depressive
disorder in adult patients who have failed to achieve satisfactory
improvement from prior antidepressant medication in the current
episode. NeuroStar is also available in other parts of the world,
including Japan, where it is listed under Japan’s national health
insurance. Additional information can be found at
www.neuronetics.com.
Investor Contact:Mike Vallie or Mark
KlausnerWestwicke
Partners443-213-0499ir@neuronetics.com
Media
Contact:EvolveMKD646.517.4220NeuroStar@evolvemkd.com
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Sep 2023 to Sep 2024